Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent
Pembrolizumab in combination with RadioTherapy for the initial treatment of previously
untreated patients with limited stage NK/T cell lymphoma who are not eligible to
chemotherapy.
It is planned to enroll 30 patients in chinese sites.
All eligible patients will be treated with standard radiotherapy and concurrent pembrolizumab
administered intravenously every 3 weeks. After 6 cycles of pembrolizumab patients with
complete remission, partial response and stable disease will continue with pembrolizumab
maintenance up to 2 years.
Patients will be followed up to 4 years from treatment start.
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)